key: cord-0694076-f1sbgboj authors: Guévremont, Diane; Tsui, Helen; Knight, Robert; Fowler, Chris J.; Masters, Colin L.; Martins, Ralph N.; Abraham, Wickliffe C.; Tate, Warren P.; Cutfield, Nicholas J.; Williams, Joanna M. title: Plasma microRNA vary in association with the progression of Alzheimer's disease date: 2022-02-05 journal: Alzheimers Dement (Amst) DOI: 10.1002/dad2.12251 sha: 7ffe5108a17248282a57dc7003e3652c31b7b65f doc_id: 694076 cord_uid: f1sbgboj INTRODUCTION: Early intervention in Alzheimer's disease (AD) requires the development of an easily administered test that is able to identify those at risk. Focusing on microRNA robustly detected in plasma and standardizing the analysis strategy, we sought to identify disease‐stage specific biomarkers. METHODS: Using TaqMan microfluidics arrays and a statistical consensus approach, we assessed plasma levels of 185 neurodegeneration‐related microRNA, in cohorts of cognitively normal amyloid β‐positive (CN‐Aβ+), mild cognitive impairment (MCI), and Alzheimer's disease (AD) participants, relative to their respective controls. RESULTS: Distinct disease stage microRNA biomarkers were identified, shown to predict membership of the groups (area under the curve [AUC] >0.8) and were altered dynamically with AD progression in a longitudinal study. Bioinformatics demonstrated that these microRNA target known AD‐related pathways, such as the Phosphoinositide 3‐kinase (PI3K‐Akt) signalling pathway. Furthermore, a significant correlation was found between miR‐27a‐3p, miR‐27b‐3p, and miR‐324‐5p and amyloid beta load. DISCUSSION: Our results show that microRNA signatures alter throughout the progression of AD, reflect the underlying disease pathology, and may prove to be useful diagnostic markers. Early detection of Alzheimer's disease (AD) is critical to the delivery of effective treatment strategies. Although it is feasible to identify known mutations in family pedigrees with a history of AD, no such routine genetic test is available to detect the sporadic, late-onset form of the disease. The apolipoprotein E (APOE)-ε4 genotype is a long-established risk factor for late-onset AD, but by itself it is not strongly predictive of progression to AD 1 and no other single mutation has demonstrated a stronger predictive value. 2 By contrast, although it is possible to quantify levels of amyloid beta (Aβ), one of the diagnostic features of AD, in cerebrospinal fluid and brain, 3 as well as anatomical changes in cortical structures, 4 it is not possible to measure these early changes without repeated use of positron emission tomography (PET) scans, magnetic resonance imaging (MRI) scans, or lumbar puncture. These expensive and/or invasive procedures are available only in highly specialized centers and are not currently suitable for population screening. 5 It is therefore vital to identify robust, easily monitored biomarkers that are accurate indicators of incipient AD and to understand how they change through the entire course of the disease. Attention has focused on blood-borne biomarkers of AD 6 ; yet no such biomarker is available in clinical practice. Indeed, despite the strong association between amyloidosis and cognitive decline, there is much debate as to whether amyloid levels in blood plasma correlate well with the disease. 6, 7 Direct measurement of Aβ (or phospho-tau) has been immensely technically challenging, despite development of new technologies. 5, 8 This is likely due to the highly aggregative nature of Aβ, low levels within blood, and a lack of knowledge regarding how export of Aβ from the brain changes with disease. Recently a growing body of evidence suggests that microRNA, a class of non-coding RNA that function by regulating gene expression at the post-transcriptional level, 9 are dysregulated in AD 10 and that blood-borne microRNA may be good candidate biomarkers of the disease. 11 Of interest, although microRNA can be detected in cerebrospinal fluid, 12 microRNA crosses the blood-brain barrier and are protected from degradation by association with protein complexes and sequestration into membrane bound vesicles, such as exosomes. 13 Indeed, recent evidence suggest that exosomes may be involved in the propagation of neurodegenerative disease 14, 15 and that exosomederived microRNA can transduce recipient cells. 16 • Plasma microRNA are dynamically expressed during the progression of Alzheimer's disease (AD). • Specific microRNA are altered at specific diseases stages and have potential diagnostic utility. • miR-195-5p and miR-324-5p are consistently regulated throughout disease progression. • miR-27a-3p, miR-27b-3p, and miR-324-5p are correlated with amyloid beta (Aβ) load. • Target analysis of biomarker microRNA reflects underlying neuropathology of AD. are mooted as crucial limiting factors in the search for blood-based biomarkers of AD. 19 We reasoned that for a biomarker to be clinically relevant, it should be independent of cohort-cohort variation, but may vary according to biofluid or method chosen for microRNA analysis. Furthermore, we predicted that plasma microRNA will vary with the progression of AD, as we found to occur during the development of amyloidosis in a mouse model of AD. 20 Here, using a standardized biofluid (plasma) and robust microRNA analysis platform (TaqMan microfluidics arrays), we identified distinctive microRNAbased biomarkers that effectively reflect the progression of AD. For further details refer to Supplementary Information. Otago We created custom-designed microfluidics arrays representing 185 microRNA correlated with neurological disease and controls (U6 snRNA and ath-miR-159a). 20 DIANA-microT v3.0 (Tarbase v7.0) and miRTarBase 7.0 http://mirtarbase.mbc.nctu.edu.tw/php/index.php were employed using the most stringent algorithm parameters to identify validated targets of the candidate microRNA biomarker for each disease stage (Figure 3 ), as well as the microRNA, which correlated with amyloidosis. Using DAVID 6.7 (http://david.ncifcrf.gov), we focused on genes expressed in brain and blood. To identify microRNA-based biomarker panels representing CN-Aβ+ (AIBL), MCI (PMed, AIBL), and AD (Otago-AD, AIBL) cohorts, we used qPCR TaqMan microfluidics arrays to quantify microRNA in plasma and expressed these relative to their respective CN controls (Table 1 and Table S1 ). The heatmap ( Figure 1 ) provides an overview of the data and includes 32 microRNA that were found to be significantly differentially expressed within at least one group (see Table S3 for fold change; FC). A flow chart summarizing our study is presented in Figure S1 . This mode of analysis not only identified microRNA previously related to MCI or AD (eg, miR-27a-3p, miR-29c-3p, miR-132-5p, miR-142-3p, miR-195-5p, miR-885-3p 24 ), but also showed considerable similarities in microRNA levels in like-cohorts and variation with disease progression. Within the AD cohorts, 75% appeared to be altered in the same direction (59% up; 16% down). It appears that the microRNA that were not validated between the AD cohorts were largely heterogeneous in the MCI group as well. Indeed, the MCI group overall showed greater heterogeneity, with only 50% of microRNA being altered in the same direction (39% up; 9% down). Of interest, of the microRNA consistently upregulated in the MCI group, 62% were also upregulated in the CN-Aβ+ group, and 75% of the microRNA regulated in the CN-Aβ+ group were also consistently regulated in the AIBL-MCI group, giving weight to the conclusion that these microRNA are altered early in the progression of AD. To interrogate these findings more rigorously, we pooled the data between like-cohorts by meta-analysis. This produced a weighted fold change (pooled estimated effect size) and 95% confidence intervals for each of the 32 microRNA. Assuming that there would be substantial heterogeneity within the MCI group, we next filtered the data by sig-nificant heterogeneity in the AD group (Log-rank; Qep test, I 2 statistics). This resulted in a set of 16 putative biomarker microRNA (Table S4 ). These microRNA are dynamically expressed across the CN-Aβ+, MCI, or AD groups relative to CN groups ( Figure 2A ). For example, three microRNA (miR-27a-3p, miR-27b-3p, miR-324-5p) were downregulated in the AD and upregulated in the CN-Aβ+ group. By contrast, six microRNA were upregulated in AD (miR-122-5p, miR-132-3p, miR-193b-3p, miR-320a-3p, miR-365-3p, and miR-885-5p) and two of these were downregulated in the CN-Aβ+ group (miR-122-5p and miR-885-5p). Only miR-195-5p and miR-335-5p showed consistent upregulation in all three disease stages but showed substantial heterogeneity in the CN-Aβ+ group. The Venn diagram ( Figure 2B ) summarizes the association of specific microRNA and disease stage, with miR-27b-3p and miR-885-5p significantly, yet dynamically, regulated in all disease groups. Thus, drawing on data from three independent cohorts, these analyses confirm that specific microRNA are dynamically expressed across the CN-Aβ+, MCI, or AD groups relative to CN groups. To prioritize candidate microRNA biomarkers from this 16-microRNA set, we ranked the importance of the individual microRNA using a statistical consensus approach. 25, 26 This involved combining the output of the differential expression analysis (P-value), the distribution of normalized Ct values (log-rank P-value), and the ability of F I G U R E 1 Heat map showing microRNA expression profiles in cognitively normal amyloid positive (CN-Aβ+), mild cognitive impairment (MCI), and Alzheimer'd disease (AD) cross-sectional cohorts. A statistically significant expression of microRNA was identified in each cohort using empirical-Bayes moderated t-tests (*; P < .05), based on log2 mean-fold changes relative to CN. The microRNA that were differentially expressed in at least one cohort are presented in the heat map as green/upregulated or red/downregulated. Each column represents a different disease stage or cohort (number of participants in parenthesis) and each row represents a single microRNA. Data were processed using GraphPad Prism v8. the microRNA to predict membership of the disease groupings (AUC). The prioritized list of the putative biomarkers for each disease stage obtained is shown in Figure 3 (and Table S5 ). In the AD group, the top ranked microRNA had the highest fold change (Table S3) To further explore the association of our candidate microRNA biomark- F I G U R E 3 Consensus ranking of microRNA and diagnostic value of disease-stage-specific putative biomarker signatures. Each of the 16 microRNA identified in the meta-analysis were ranked using three independent criteria. The three rankings per microRNA were then summed to provide a final rank. Lower total rank sums were given the highest ranking. The three ranking criteria used were (1) differential expression (P-value; refer Table S3 ), (2) distribution of normalized Ct values (log-rank tests; P-values; refer Table S4) (Table S7) . AUCs for each microRNA were assessed singly in line with the Peduzzi constraints. miR-29c-3p and miR-335-5p showed the equal strongest AUCs in the CN-Aβ+ group, whereas, miR-142-3p, miR-148a-3p, and miR-27b-3p were strongest in the MCI group and miR-27a-3p showed the strongest in the AD group. Furthermore, we found using Pearson correlations that Aβ load (centiloid values; Table 1 ) in the AD group was significantly correlated with miR-27a-3p (r = 0.466; P = .002), miR-27b-3p (r = 0.391; P = .012), and miR-324-5p (r = 0.406; P = .009). Together these analyses reinforce that these microRNA may have prognostic utility. Using a bioinformatic approach, we probed the association of the can- Resistance and Long-term potentiation. Alongside the observations that the candidate biomarker microRNA have been shown previously to be altered in either AD plasma and/or post-mortem tissue (Table S8) , this analysis reinforces the connection between the candidate microRNA biomarkers and the pathology underlying the progressive stages of AD. 17 This failure in replication may be due to inconsistent blood-fraction methods and variation in microRNA analysis. 19 Using an innovative statistical consensus approach and holding the blood fraction, technical platform, and mode of analysis constant, we have determined a unique set of plasma microRNA associated with AD, which rise above innate heterogeneities found within populations. It is notable that we have shown for the first time that plasma microRNA levels are altered before symptoms manifest and vary dynamically with disease progression. The individual microRNA that we have highlighted have all been associated previously with AD, and using bioinformatics, we have shown that our candidate microRNA converge on PI3K-Akt signalling, a pathway with a well-established relationship with the molecular pathology underlying AD, including neurofibrillary tangles and microglial and astroglial inflammasome regulation. 28 Thus the microRNA compiled in our study are likely a valid set of biomarkers reflecting the progression of AD. Our work particularly highlights elevated miR-29c-3p and miR-335-5p levels as novel biomarkers of early amyloidosis. Levels of both microRNA have been shown previously to be altered in AD biofluids (refer Table S8 ), and miR-29c-3p and BACE1 as well as miR-335-5p and Aβ levels are inversely correlated, 29, 30, 31 suggesting that they both contribute directly to cerebral amyloid levels. Furthermore, both miR-29c-3p and miR-335-5p have been shown to enhance memory performance in the Morris water maze. 31,32 miR-335-5p is a neuronally enriched microRNA and a proposed key regulator of AD-related gene networks. 33 Our bioinformatic analysis showed that together these microRNA map to Inflammatory Response and Glioblastoma as well PI3K and mTOR pathways. Indeed, miR-29c-3p is known to protect against inflammasome activation in microglia, 34 suggesting a role in neuroprotection. Our finding that miR-335-5p is upregulated in plasma supports the findings of Cheng et al., who showed this microRNA was upregulated in extracellular vesicles isolated from plasma from the AIBL-AD cohort. 35 Of interest, two previous studies have shown that miR-335-5p is downregulated in post-mortem brain, thus suggesting that AD is associated with an increase in the export of miR-335-5p into extracellular vesicles. Within our biomarker signature we found that expression of most microRNA varied across the progression of the disease. However, our cross-sectional study showed that miR-195-5p and miR-335-5p were consistently elevated, but it is notable that we found that their levels were reducing with the progression of the disease (while remaining above control levels), in the AIBL longitudinal sub-group. Upregulation of miR-195-5p may also be part of a neuroprotective response, as this microRNA inhibits the expression of both BACE1 and APP 36 and apoptosis. 37 intriguing that recently a genetic variation in the promoter of miR-142 (rs2526377:A > G), which results in reduced expression, was shown to be significantly associated with a reduced risk of AD. 46 Thus further investigations into the role of miR-142 in AD are warranted. The microRNA correlated with the amyloid load (centiloid values) in individuals with advanced AD mapped to the HIF-1 Signaling pathway. This pathway is interlinked with VEGF, MAPK, and PI3K signaling and promotes amyloidogenic processing of APP. 47 The plasticityrelated pathways Neurotrophin Signaling and Long-term potentiation were also mapped to this group. miR-27a-3p, miR-27b-3p, and miR-324-5p have been shown previously to be altered in blood or postmortem brain tissue (Table S8 ). Indeed downregulation of miR-324-5p has been mooted to contribute to synaptic loss during aging, 48 whereas miR-27b-3p is considered a proinflammatory microRNA. 49, 50 Of interest, miR-27a-3p targets SERPINA3, which encodes a serine protease inhibitor associated with the APOE ε4 genotype, inflammation, and amyloid polymerization. 51 Together these bioinformatic analyses highlight a strong relationship between our candidate biomarker microRNA inflammation and amyloidosis, lending weight to the conclusion that these plasma biomarkers reflect the disease processes occurring within the brain. In summary, the plasma microRNA highlighted by our studies, derived by using a statistical consensus approach using multiple cohorts, vary with disease progression in the AIBL longitudinal study and reflect known steps underlying AD neuropathology; therefore, may be useful in disease risk prediction in clinical practice. Our early signature likely predicts underlying pathology before individuals become symptomatic. These data are unique and need to be strengthened by further in-depth analysis of pre-symptomatic individuals, 52 validation in other cohorts, and by analysis of neuronal exosomederived microRNA in plasma or CSF. 53 It will also be important to understand the influence of other endophenotypes such as APOE ε4 status on the plasma levels of these microRNA 54 as well as sex and ethnicity of the study cohorts. 55 Furthermore, it will be important to explore the specificity of the biomarker by testing whether the same or different microRNA are useful in the early diagnosis of other neurodegenerative diseases. These data will be highly valuable for improved criteria of inclusion into clinical trials where currently available cognitive behavioral and drug therapies can be further tested 56, 57, 58 and thus the onset of disease can be delayed. Overall, we have shown that biomarkers are dynamic, altering with disease progression, thus emphasizing the need for longitudinal biomarker testing. The transition to our later signature may further identify at-risk individuals and be useful in prioritizing individuals for more highly specialized testing. Neurological Foundation of New Zealand ANZMES the ME/CFS association of New Zealand (through the institution) Donations from families with ME/CFS (through the institution) Honorarium Invited speaker Complex Chronic Disease Support -Bay of Plenty New Zealand Governance Board member of the Maurice Wilkins Centre of Excellence -support to travel to governance and sci New Zealand Ministry of Health Covid-19 Vaccine Independent Safety Monitoring Board Risdiplan for Spinal Muscular Atrophy, 1 day advisory Board Cladribine in Multiple Sclerosis, Merk Serono, 1-day Advisory Board; Risdiplan in Spinal Musculr Atrophy, Roche 1-day Advisory Board President of the Australasian Neuroscience Society Governance Board of the Maurice Wikins Centre of Research Excellence Southern District Health Board Director NZ Creutzfeldt Jakob Disease Surveillance Registry (paid via University of Otago) Medical Advisor to NZ CJD family support group (unpaid) The genetic risk of Alzheimer's disease beyond APOE ε4: systematic review of Alzheimer's genetic risk scores Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: the GR@ACE project Amyloid biomarkers in Alzheimer's disease Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition High performance plasma amyloid-β biomarkers for Alzheimer's disease The past and the future of Alzheimer's disease fluid biomarkers Comparative analyses of plasma amyloidβ levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging. Alzheimer's Dement: J Alzheimer's Assoc Regulation of microRNA function in animals The regulation of microRNAs in Alzheimer's disease MicroRNAs as peripheral biomarkers in aging and age-related diseases Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways Extracellular vesicles and neurodegenerative Diseases Packaging of prions into exosomes is associated with a novel pathway of PrP processing Alzheimer's disease pathology propagation by exosomes containing toxic amyloidbeta oligomers Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Systematic review of miRNA as biomarkers in Alzheimer's Dis Meta-analysis of gene expression changes in the blood of patients with mild cognitive impairment and Alzheimer's disease dementia Comparing biological markers of Alzheimer's disease across blood fraction and platforms: comparing apples to oranges Circulating plasma microRNAs are altered with amyloidosis in a mouse model of Alzheimer's Disease Assessing sample and miRNA profile quality in serum and plasma or other biofluids Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool Enrichr: a comprehensive gene set enrichment analysis web server 2016 update Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid Validation of MicroRNA biomarkers for Alzheimer's disease in human cerebrospinal fluid MicroRNAs in human cerebrospinal fluid as biomarkers for Alzheimer's disease A simulation study of the number of events per variable in logistic regression analysis Altered insulin signaling in Alzheimer's disease brain -Special emphasis on PI3K-Akt Pathway Downregulated miR-29c correlates with increased BACE1 expression in sporadic Alzheimer's disease Alterations in Striatal microRNA-mRNA networks contribute to neuroinflammation in multiple system atrophy MiR-335-5p inhibits β-Amyloid (Aβ) accumulation to attenuate cognitive deficits through targeting cjun-N-terminal Kinase 3 in Alzheimer's disease Lower serum levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer's disease Analysis of microRNA and gene expression profiles in Alzheimer's disease: a metaanalysis approach miR-29c-3p inhibits microglial NLRP3 inflammasome activation by targeting NFAT5 in Parkinson's disease Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment MicroRNA-195 downregulates Alzheimer's disease amyloid-β production by targeting BACE1 MiR-195 alleviates oxygen-glucose deprivation/reperfusion-induced cell apoptosis via inhibition of IKKαmediated NF-κB pathway MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer's disease pathogenesis. Mole Psychiat MicroRNA-195 prevents dendritic degeneration and neuron death in rats following chronic brain hypoperfusion Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease Circulating miRNA biomarkers for Alzheimer's disease The long non-coding RNA TP73-AS1 interacted with miR-142 to modulate brain glioma growth through HMGB1/RAGE pathway miR-142-3p Is a key regulator of IL-1β-dependent synaptopathy in neuroinflammation A functional variant in the miR-142 promoter modulating its expression and conferring risk of Alzheimer's disease Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and betaamyloid generation Astrocytic miR-324-5p is essential for synaptic formation by suppressing the secretion of CCL5 from astrocytes MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferatoractivated receptor gamma (PPARgamma) mRNA destabilization MicroR-NAs: roles in regulating neuroinflammation Alzheimer's risk factors age, APOE genotype, and sex drive distinct molecular pathways Statistical methods for dementia risk prediction and recommendations for future work: a systematic review Exosome biomarkers revolutionize preclinical diagnosis of neurodegenerative diseases and assessment of treatment responses in clinical trials Association of β-Amyloid and apolipoprotein E ε4 with memory decline in preclinical Alzheimer's Disease Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need Cognitive therapy for dementia patients: a systematic review A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial Clinical trials of new drugs for Alzheimer's disease Plasma microRNA vary in association with the progression of Alzheimer's disease The authors acknowledge the expert assistance of Jill Leichter, Christina Edgar, and Barbara Logan. Joanna M. Williams https://orcid.org/0000-0003-3936-2220